**Protocol Title:** Molecular Analysis for Therapy Choice (MATCH) - Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma

**Target Population:**
- Advanced Malignant Solid Neoplasm
- Neoplasm
- Recurrent Malignant Solid Neoplasm
- Recurrent Plasma Cell Myeloma
- Refractory Malignant Neoplasm
- Refractory Plasma Cell Myeloma

**Summary:** This Phase II Trial studies how well treatment that is directed by genetic testing works in patients with Solid Tumors or Lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. The primary objective of this trial is to evaluate the proportion of patients with Objective Response (OR) to targeted study agent(s) in patients with Advanced Refractory Cancers / Lymphomas / Multiple Myeloma.

**Key Inclusion Criteria:**
- Histologically documented Solid Tumors or histologically confirmed diagnosis of Lymphoma or Multiple Myeloma requiring therapy and that has progressed following at least one line of standard systemic therapy and/or for whose disease no standard treatment exists that has been shown to prolong survival.
- Patients must meet one of the following criteria:
  - Patients with Multiple Myeloma are to have a bone marrow aspirate to obtain tumor cells.
  - Formalin-fixed paraffin-embedded (FFPE) tumor tissue block(s) are available for submission following pre-registration (not applicable for bone marrow aspirate specimens); criteria for the submission of FFPE tissue are:
    - Tissue must have been collected within 6 Months prior to pre-registration.
    - Patient has not received any intervening therapy that is considered to be targeted for their cancer since the collection of the tumor sample; they may have received cytotoxic chemotherapy for up to 4 cycles, but must not have had response to such treatment.
- Patient must not require the use of full dose Coumarin-derivative Anticoagulants such as Warfarin.
  - Low Molecular Weight Heparin is permitted for prophylactic or therapeutic use.
  - Factor X Inhibitors are permitted.
- Patients must not have any uncontrolled intercurrent illness.
- Any prior therapy, radiotherapy (except palliative radiation therapy of 30 gray [Gy] or less), or major surgery must have been completed ≥ 4 Weeks prior to start of treatment.
- Patients must have discontinued steroids ≥ 1 Week prior to registration and remain off steroids thereafter, with some exceptions.
  - Patients with Glioblastoma (GBM) must have been on stable dose of steroids, or be off steroids, for 1 Week prior to registration to treatment.

**Contacts:**
- **Principal Investigator:** Marc Matrana, MD
- **Research Nurses (RN):**
  - Amanda Woolery (amanda.woolley@ochsner.org, ext. 20275)
  - Sharon Jerdonek (sharon.jerdonek@ochsner.org, ext. 23929)

**For additional information:** [https://clinicaltrials.gov/ct2/show/NCT02465060](https://clinicaltrials.gov/ct2/show/NCT02465060)